Tag: Eversense CGM
Ascensia names leader for CGM business
February 6, 2024HME News Staff
TOKYO – PHC Holdings Corp., the parent company of Ascensia Diabetes Care, and Senseonics Holdings have announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of president of CGM at Ascensia Diabetes Care effective today, Feb. 6, 2024. Hansen will be responsible for the global commercialization and growth of the Eversense CGM, which is currently available in the U.S. and select European markets. “Eversense is a game-changer for people with diabetes...
Ascensia featured in film series
December 6, 2023HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care is participating in a new film series featuring the story of patient advocate and Eversense user Troy Ita. The “Connecting the Dots” series, which brings into focus the evolution of medical technologies, includes Ascensia’s mini-documentary style video focusing on Troy’s journey with diabetes and how the evolution in continuous glucose monitoring technology has supported him to live a fuller, less interrupted life. In particular,...
Ascensia expands payment assistance program
May 10, 2023HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care, maker of the Contour Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense Continuous Glucose Monitoring (CGM) Systems, announces that it has significantly expanded Eversense PASS, a payment assistance and simple savings program designed to enhance affordability and access to the Eversense E3. Under the new and improved program, there will be more people with diabetes eligible for assistance paying for the system and...
Ascensia launches Eversense E3 in US
April 5, 2022HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care has launched the next-generation Eversense E3 Continuous Glucose Monitoring System for patients in the U.S., alongside the new Eversense PASS savings program. Eversense E3, which is developed be Senseonics Holdings, was approved for use up to six months by the U.S. Food and Drug Administration earlier this year, making it the longest lasting CGM sensor available in the country. “We are thrilled to offer Eversense E3 to people with diabetes in...